Breast Cancer
Observational Cohort Study: Chemotherapy Decisions and Outcomes in Women age 65 or Older with Operable, Newly Diagnosed Breast Cancer [CALGB 369901]
Principal Investigator:
James Hannigan, M.D.
Adventist La Grange Hospital
(708) 579-3418
Contact: Terri Crestani, MPH
Quality of Life in Younger Breast Cancer Survivors [ECOG 2Z04]
Principal Investigator:
Elyse Schneiderman, M.D.
Adventist Hinsdale Hospital
(630) 654-1790
Contact: Jan Wilson, R.N.
Negative Lymph Nodes
Endocrine Therapy with or without Inhibition of EGF and HER2 Growth Factor Receptors: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Fulvestrant with or without Lapatinib (GW572016) for Postmenopausal Women with Hormone-Receptor Positive Advanced Breast Cancer [CALGB 40302]
Principal Investigator:
James Hannigan, M.D.
Adventist La Grange Hospital
(708) 579-3418
Contact: Terri Crestani, MPH
A Randomized Clinical Trial of Adjuvant Chemotherapy for Radically Resected Loco-Regional Relapse of Breast Cancer [NSABP B-37]
Principal Investigator:
Renee Jacobs, M.D.
Adventist La Grange Hospital
(708) 579-3418
Contact: Terri Crestani, MPH
A Phase III Randomized Trial of Anastrozole versus Anastrozole and Fulvestrant as First Line Therapy for Post-Menopausal Women with Metastatic Breast Cancer [SWOG 0226 CTSU]
Principal Investigator:
Renee Jacobs, M.D.
Adventist La Grange Hospital
(708) 579-3418
Contact: Terri Crestani, MPH
A Phase II Trial of Capecitabine in Combination with the Famesyltransferase Inhibitor, R115777 (Tipifamib, Zamestra) in Patients with Metastatic Breast Cancer [ECOG 1103]
Principal Investigator:
Elyse Schneiderman, M.D.
Adventist Hinsdale Hospital
(630) 654-1790
Contact: Jan Wilson, R.N.
A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide followed by Paclitaxel with Bevacizumab or Placebo in Patients with Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer [ECOG 5103]
Principal Investigator:
Renee Jacobs, M.D.
Adventist La Grange Hospital
(708) 579-3418
Contact: Terri Crestani, MPH
A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide followed by Paclitaxel with Bevacizumab or Placebo in Patients with Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer [ECOG 5103]
Principal Investigator:
Elyse Schneiderman, M.D.
Adventist Hinsdale Hospital
(630) 654-1790
Contact: Jan Wilson, R.N.
Receptor-Positive
Endocrine Therapy in Combination with anti-VEGF Therapy: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Endocrine Therapy Alone or Endocrine Therapy plus Bevacizumab (NSC 704865; IND 7921) for Women with Hormone Receptor-Positive Advanced Breast Cancer [CALGB 40503]
Principal Investigator:
Renee Jacobs, M.D.
Adventist La Grange Hospital
(708) 579-3418
Contact: Terri Crestani, MPH
A Randomized, Phase III, Double-Blind, Placebo-Controlled Trial of First-Line Chemotherapy and Trastuzumab with or without Bevacizumab for Patient with HER-2/NEU Over-Expressing Metastatic Breast Cancer [ECOG 1105]
Principal Investigator:
Elyse Schneiderman, M.D.
Adventist Hinsdale Hospital
(630) 654-1790
Contact: Jan Wilson, R.N.
BIG 2-06, ALTTO: Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Study: A randomized, multi-center, open-label, phase III study of adjuvant lapatinib, trastuzumab, their sequence and their combination in patients with HER2/ErbB2 positive primary breast cancer [NCCTG 063D]
Principal Investigator:
Renee Jacobs, M.D.
Adventist La Grange Hospital
(708) 579-3418
Contact: Terri Crestani, MPH
A Randomized Phase III Trial of Neoadjuvant Therapy for Patients with Palpable and Operable HER2-Positive Breast Cancer, Comparing the Combination of Trastuzumab plus Lapatinib to Trastuzzumab and to Lapatinib Administered with Weekly Paclitaxel following AC Accompanied by Correlative Science Studies to Identify Predictors of Pathologic Complete Response [NSABP B-41]
Principal Investigator:
Elyse Schneiderman, M.D.
Adventist Hinsdale Hospital
(630) 654-1790
Contact: Jan Wilson, R.N.
A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tampxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women with Hormone Receptor Positive Breast Cancer [NSABP B-42]
Principal Investigator:
Elyse Schneiderman, M.D.
Adventist Hinsdale Hospital
(630) 654-1790
Contact: Jan Wilson, R.N.
Other
A Clinical Trial Comparing Anastrozole with Tamoxifen in Postmenopausal Patients with Ductal Carcinoma in Situ (DCIS) Undergoing Lumpectomy with Radiation Therapy [NSABP B-35]
Principal Investigator:
Elyse Schneiderman, M.D.
Adventist Hinsdale Hospital
(630) 654-1790
Contact: Jan Wilson, R.N.
A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide followed by Paclitaxel with Bevacizumab or Placebo in Patients with Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer [ECOG 5103]
Principal Investigator:
Renee Jacobs, M.D.
Adventist La Grange Hospital
(708) 579-3418
Contact: Terri Crestani, MPH
Program for the Assessment of Clinical Cancer Tests: Trial Assigning Individualized Options for Treatment: The TAILORx Trial [PACCT-1]
Principal Investigator:
Elyse Schneiderman, M.D.
Adventist Hinsdale Hospital
(630) 654-1790
Contact: Jan Wilson, R.N.
Study of Tamoxifen and Raloxifene for the Preventon of Breast Cancer [NSABP P-2]
Principal Investigator:
Elyse Schneiderman, M.D.
Adventist Hinsdale Hospital
(630) 654-1790
Contact: Jan Wilson, R.N.
Double-Blind, Randomized Phase Iib Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo when Administered in Combination with Paclitaxel in Patients with Locally-Recurrent or Metastatic Breast Cancer [NU 07B1]
Principal Investigator:
Elyse Schneiderman, M.D.
Adventist Hinsdale Hospital
(630) 654-1790
Contact: Jan Wilson, R.N.
Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer [SWOG 0307 CTSU]
Principal Investigator:
Renee Jacobs, M.D.
Adventist La Grange Hospital
(708) 579-3418
Contact: Terri Crestani, MPH